In children with Alagille syndrome, maralixibat, an apical, sodium-dependent, and bile acid transport inhibitor, is the first IBAT inhibitor that has shown durable and clinically meaningful improvements in cholestasis [74]. The gene discussed is SLC10A2; the disease is Alagille syndrome.